1. Home
  2. IOVA vs KLC Comparison

IOVA vs KLC Comparison

Compare IOVA & KLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IOVA
  • KLC
  • Stock Information
  • Founded
  • IOVA 2007
  • KLC 1969
  • Country
  • IOVA United States
  • KLC United States
  • Employees
  • IOVA N/A
  • KLC N/A
  • Industry
  • IOVA Biotechnology: Biological Products (No Diagnostic Substances)
  • KLC
  • Sector
  • IOVA Health Care
  • KLC
  • Exchange
  • IOVA Nasdaq
  • KLC NYSE
  • Market Cap
  • IOVA 2.6B
  • KLC 2.4B
  • IPO Year
  • IOVA N/A
  • KLC 2024
  • Fundamental
  • Price
  • IOVA $5.82
  • KLC $20.15
  • Analyst Decision
  • IOVA Strong Buy
  • KLC Buy
  • Analyst Count
  • IOVA 9
  • KLC 8
  • Target Price
  • IOVA $23.06
  • KLC $31.75
  • AVG Volume (30 Days)
  • IOVA 7.2M
  • KLC 484.6K
  • Earning Date
  • IOVA 02-26-2025
  • KLC 03-20-2025
  • Dividend Yield
  • IOVA N/A
  • KLC N/A
  • EPS Growth
  • IOVA N/A
  • KLC N/A
  • EPS
  • IOVA N/A
  • KLC 0.07
  • Revenue
  • IOVA $90,858,000.00
  • KLC $2,634,075,000.00
  • Revenue This Year
  • IOVA $13,803.28
  • KLC $7.08
  • Revenue Next Year
  • IOVA $167.55
  • KLC $7.37
  • P/E Ratio
  • IOVA N/A
  • KLC $283.96
  • Revenue Growth
  • IOVA 12751.20
  • KLC 6.76
  • 52 Week Low
  • IOVA $5.05
  • KLC $17.05
  • 52 Week High
  • IOVA $18.33
  • KLC $29.89
  • Technical
  • Relative Strength Index (RSI)
  • IOVA 49.38
  • KLC N/A
  • Support Level
  • IOVA $5.44
  • KLC N/A
  • Resistance Level
  • IOVA $5.80
  • KLC N/A
  • Average True Range (ATR)
  • IOVA 0.31
  • KLC 0.00
  • MACD
  • IOVA 0.09
  • KLC 0.00
  • Stochastic Oscillator
  • IOVA 82.43
  • KLC 0.00

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

About KLC KINDERCARE LEARNING COMPANIES INC

KinderCare Learning Companies Inc is a private provider of early childhood education and care services (ECE) in the United States. It serves children ranging from 6 weeks to 12 years of age across its market- leading footprint of around 1,480 early childhood education centers with a capacity of more than 194,000 children and contracts for more than 650 before- and after-school sites located in 40 states and the District of Columbia. Its three go-to-market channels are KinderCare Learning Centers, KinderCare Education at Work, and Champions.

Share on Social Networks: